Study of Patient Preferences Regarding a New Class of Antihypertensive Medications: A Discrete Choice Experiment in Ukraine
Author(s)
Tamara Mahanova, PhD, Natalia Tkachenko, Professor.
Department of Organization and economy of pharmacy, Zaporizhzhia state medical and pharmaceutical university, Zaporizhzhia, Ukraine.
Department of Organization and economy of pharmacy, Zaporizhzhia state medical and pharmaceutical university, Zaporizhzhia, Ukraine.
OBJECTIVES:
This study aimed to assess patient preferences regarding a new class of antihypertensive medications in Ukraine. Understanding these preferences is crucial for evaluating the acceptance of innovative therapies and determining key factors affecting treatment adherence.
METHODS: A discrete choice experiment was conducted with hypertensive patients in Ukraine. Six attributes of the new injectable antihypertensive drugs were identified: frequency of use, blood pressure reduction, risk of side effects (weight gain), injection site reactions, infections, and cost. The OLS method was used to create the choice set and evaluate design effectiveness. Bayesian modeling assessed patient preferences for each attribute. A survey of 200 individuals was conducted to ensure reliable results.
RESULTS:
Patients preferred drugs with a lower risk of side effects (0% and 3%) and a longer duration of action (6 months). The averaged utility scores indicated that patients were concerned about potential weight gain during six months of treatment and focused on the effectiveness of systolic blood pressure reduction. Duration of action and risk of upper respiratory infections had less impact on decision-making. The design showed high D-efficiency (621.01), ensuring reliable results.
CONCLUSIONS: The study provides valuable insights into how patients evaluate innovative antihypertensive therapies. The identified preferences can inform the development of treatment options that better align with patient expectations. Further research will explore preference heterogeneity among different patient groups, willingness to pay for innovative therapies and acceptance of associated risks and benefits.
This study aimed to assess patient preferences regarding a new class of antihypertensive medications in Ukraine. Understanding these preferences is crucial for evaluating the acceptance of innovative therapies and determining key factors affecting treatment adherence.
METHODS: A discrete choice experiment was conducted with hypertensive patients in Ukraine. Six attributes of the new injectable antihypertensive drugs were identified: frequency of use, blood pressure reduction, risk of side effects (weight gain), injection site reactions, infections, and cost. The OLS method was used to create the choice set and evaluate design effectiveness. Bayesian modeling assessed patient preferences for each attribute. A survey of 200 individuals was conducted to ensure reliable results.
RESULTS:
Patients preferred drugs with a lower risk of side effects (0% and 3%) and a longer duration of action (6 months). The averaged utility scores indicated that patients were concerned about potential weight gain during six months of treatment and focused on the effectiveness of systolic blood pressure reduction. Duration of action and risk of upper respiratory infections had less impact on decision-making. The design showed high D-efficiency (621.01), ensuring reliable results.
CONCLUSIONS: The study provides valuable insights into how patients evaluate innovative antihypertensive therapies. The identified preferences can inform the development of treatment options that better align with patient expectations. Further research will explore preference heterogeneity among different patient groups, willingness to pay for innovative therapies and acceptance of associated risks and benefits.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR148
Topic
Patient-Centered Research
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Geriatrics